Montelukast

Montelukast Soldium
N,N,[R-(E)]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2- (1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl] cyclopropaneacetic acid, monosodium salt
CAS number not known	ATC code not known
Chemical formula	C₃₅H₃₅ClNNaO₃S
Molecular weight	608.18
Bioavailability	>99% bound in plasma
Metabolism	Hepatic
Elimination half-life	2.7 to 5.5 hours (normal liver function)
Excretion	not known
Pregnancy category	not known
Legal status	not known
Routes of administration	Oral
Formulation(s)	Singulair: 4mg, 5mg, 10mg

Montelukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies. It is not useful for the treatment of acute asthma attacks, so patients should also be supplied with rescue medication, such as an albuterol inhaler. Montelukast blocks the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT₁, thus inhibiting bronchoconstriction. The medication is categorised in the FDA pregnancy category B.

Montelukast is marketed by Merck & Co. with the brand name Singulair®. It is available as oral tablets, chewable tablets, and oral granules.

External links

	This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Merck & Co., Inc.
Corporate Directors: Lawrence Bossidy \| William Bowen \| Richard Clark \| Johnnetta Cole \| William Harrison \| William Kelley \| Rochelle Lazarus \| Thomas Shenk \| Anne Tatlock \| Samuel Thier \| Wendell Weeks \| Peter Wendell
Key products: Indinavir \| Aprepitant \| Alendronate \| Rizatriptan \| Finasteride \| Montelukast \| Rofecoxib \| Ezetimibe/simvastatin \| Ezetimibe \| Simvastatin \| The Merck Index \| The Merck Manual
Annual Revenue: $22.9 billion USD (2% FY 2004) \| Employees: 63,000 \| Stock Symbol: NYSE: MRK \| Website: www.merck.com

The content of this page is retrieved from http://en.wikipedia.org/wiki/Montelukast under GFDL